FSIN||Progressive Pulmonary Fibrosis (PPF) - Diagnosis and Treatment in the ATS/ERS/JRS/ALAT Guideline Read more about FSIN||Progressive Pulmonary Fibrosis (PPF) - Diagnosis and Treatment in the ATS/ERS/JRS/ALAT Guideline
SGOFV2023COM||INBUILD® Trial Efficacy (autoimmune ILD patients) Read more about SGOFV2023COM||INBUILD® Trial Efficacy (autoimmune ILD patients)
SGOFV2023COM||INBUILD® Trial Population and Baseline Medications Read more about SGOFV2023COM||INBUILD® Trial Population and Baseline Medications
SGOFV2022COM||The key to managing progression in SSc-ILD patients Read more about SGOFV2022COM||The key to managing progression in SSc-ILD patients
SGOFV2023COM||Largest prospective Phase III clinical trial in patients with SSc-ILD Read more about SGOFV2023COM||Largest prospective Phase III clinical trial in patients with SSc-ILD
A1-R101||A2-R101||RA-ILD DELPHI CONSENSUS SCREENING ALGORITHM Read more about A1-R101||A2-R101||RA-ILD DELPHI CONSENSUS SCREENING ALGORITHM
A1-R101||A2-R101||How to identify patients with RA-ILD who can benefit from OFEV Read more about A1-R101||A2-R101||How to identify patients with RA-ILD who can benefit from OFEV
FSIN||How to recognize ILD in PPF patients with CTD Read more about FSIN||How to recognize ILD in PPF patients with CTD
SGOFV2023COM||Vigilance and proactivity are critical in reducing the burden of disease Read more about SGOFV2023COM||Vigilance and proactivity are critical in reducing the burden of disease
SGOFV2023COM||Regular screening is critical as ILD can develop early Read more about SGOFV2023COM||Regular screening is critical as ILD can develop early
